Spanish Energy Services Stock News

Bankinter, S.A. has reported past fourth-quarter 2025 results, with net income of €278.47 million compared with €221.92 million a year earlier. The sharp year-on-year increase in quarterly net income highlights how Bankinter’s underlying profitability evolved through the end of 2025. Next, we will examine how Bankinter’s stronger fourth-quarter net income shapes the company’s broader investment narrative for investors. Find companies with promising cash flow potential yet trading below their...

Banco Bilbao Vizcaya Argentaria (BME:BBVA) has launched a new share buyback program. The buyback is part of the bank's broader capital management approach, focusing on returning excess capital to shareholders. The program is intended to reduce the number of shares in circulation and adjust BBVA's capital structure. BBVA is a large banking group with a presence across retail, corporate, and investment banking, as well as payment and digital services. For investors, a new buyback program can...

An arbitration panel ruled in favor of Venture Global’s Calcasieu Pass unit in its past dispute with Repsol over the timing of LNG commercial operations and awarded fees to the US exporter, while Repsol reviews the decision. This outcome raises questions for Repsol’s long-term LNG contracting framework, as it clarifies how “Reasonable and Prudent Operator” standards are interpreted in arbitration. We’ll now examine how this arbitration outcome, and the clarification around LNG delivery...

In recent days, UBS issued a sell rating on Spanish insurer Mapfre, while assigning a buy rating to its peer Linea Directa. This contrasting analyst stance comes as Mapfre showed relative resilience on a weak Spanish equity market day, drawing extra investor attention. We will now examine how UBS’s bearish stance shapes Mapfre’s investment narrative and what it might mean for investor perception. Uncover the next big thing with financially sound penny stocks that balance risk and reward.What...

Sacyr (BME:SCYR) has drawn fresh investor attention after announcing a 1 for 25.19526 stock split or significant stock dividend effective 13 January 2026, coinciding with reported 11% operating cash flow growth. See our latest analysis for Sacyr. At a share price of €3.918, Sacyr’s recent 2.1% 1 month share price return sits against a much stronger 1 year total shareholder return of 24.4% and 5 year total shareholder return of 160.9%. This suggests that longer term momentum has been more...

Most readers would already know that Faes Farma's (BME:FAE) stock increased by 9.4% over the past three months. Given...

In January 2026, Telefónica, S.A. withdrew its April 2023 omnibus shelf registration in the U.S., shortly after issuing €900 million of callable 4.381% green bonds through Telefónica Emisiones, S.A.U. as fixed-rate corporate debt. This sequence suggests Telefónica may be prioritizing targeted sustainable financing over maintaining broad, pre-registered capital-raising flexibility across equity, debt and rights instruments. We will now examine how Telefónica’s recent €900 million green bond...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Key Insights Agile Content's estimated fair value is €3.13 based on 2 Stage Free Cash Flow to Equity Current share...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...

The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...

Banco Bilbao Vizcaya Argentaria (BME:BBVA) has announced a new share buyback program. Banco Bilbao Vizcaya Argentaria has also provided investors with an update on its ongoing share repurchase activities. The current share price is €20.78, with the stock up 108.4% over the past year. For investors, this new buyback plan puts capital allocation back in focus at BME:BBVA. The stock has logged a 108.4% return over the past year and a 5.1% gain over the past month. The year-to-date move of 2.0%...

Banco Santander (BME:SAN) has completed a A$550 million fixed income offering. The transaction adds a fresh funding source in the Australian capital market. At the same time, investors are watching potential U.S. tariffs on European nations and how these could affect large cross border lenders. As one of Europe’s largest banking groups with a broad international footprint, Banco Santander operates across retail, corporate and investment banking. A new A$550 million fixed income deal gives...

The European market has shown resilience, with the STOXX Europe 600 Index rising 0.77% amid positive economic data and earnings reports, while Germany's economy emerged from a two-year recession with modest growth. In this environment of mixed signals and cautious optimism, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors looking to capitalize on undervaluation in the market.

Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of eDreams ODIGEO S.A...

Telefónica (BME:TEF) has just completed a €2.65b green financing package, pairing new callable bonds with undated subordinated securities, while earnings estimates and 2025 growth guidance have recently been marked higher and reaffirmed. See our latest analysis for Telefónica. Even with the new €2.65b green financing and higher earnings estimates, Telefónica’s recent share price performance has been weak. The 90 day share price return is 28.81% and the year to date share price return is a...

As European markets show resilience with the pan-European STOXX Europe 600 Index rising by 0.77%, investors are keenly watching for opportunities amid mixed performances in major stock indexes like Germany’s DAX and France’s CAC 40. In this dynamic environment, identifying stocks with strong fundamentals becomes crucial, as these characteristics can help navigate through economic fluctuations and capitalize on potential growth prospects.

The European market has shown resilience, with the STOXX Europe 600 Index gaining ground amid positive economic data and mixed earnings results across major stock indexes. In this dynamic environment, dividend stocks can offer a steady income stream and potential stability, making them an appealing option for investors seeking to navigate the current market conditions.

Vidrala's (BME:VID) stock up by 6.8% over the past three months. Given its impressive performance, we decided to study...

Key Insights Institutions' substantial holdings in HBX Group International implies that they have significant influence...

Key Insights The projected fair value for Meliá Hotels International is €12.02 based on 2 Stage Free Cash Flow to...

The European Investment Bank has agreed a €175 million green loan with Iberdrola (BME:IBE) to fund two new wind farms in northern Portugal, drawing fresh attention to the group’s renewables-focused equity story. See our latest analysis for Iberdrola. That green loan arrives as Iberdrola’s €18.57 share price sits on a 90 day share price return of 8.85% and a slightly negative year to date share price return. Longer term total shareholder returns of 44.82% over one year and around 90% over...

Operational gains and buyback move Endesa into focus Endesa (BME:ELE) is back on investors’ radar after 9‑month EBITDA rose 9% and Funds From Operations climbed 29%, alongside a €500 million share buyback and a customer expansion deal with MasOrange. See our latest analysis for Endesa. At a share price of €30.88, Endesa has seen a 6.01% 3 month share price return, while its 1 year total shareholder return of 51.80% suggests stronger momentum over a longer horizon despite a slightly weaker...

Pharma Mar recently reported a sharp improvement in profitability, with EBITDA reaching €25.1 million, as high‑margin license payments and rapidly growing global royalties from its cancer drug Zepzelca, including in the US and China, boosted results. Beyond the headline earnings turnaround, the breadth of Zepzelca uptake across major markets underscores how royalty‑driven income is becoming a more central earnings pillar for Pharma Mar. We’ll now examine how the stronger high‑margin royalty...